Abbott announces starting of Asia-Pacific Diet R&D Center Abbott , the global healthcare firm, today announced the starting of the Abbott Asia-Pacific Nutrition Research & Development Middle at Singapore’s Biopolis Research Park.S., and Singapore’s first diet R&D site creating science-based nutritional products for infants, children and adults. The role of nourishment in the development of the mind, bones, immune system and metabolic function of infants and kids will be key areas of research and innovation. Liepmann, executive vice president, Abbott Diet. Related StoriesNutrition technology must transformation to feed exploding world population, say worldwide researchersProper iodine nutrition necessary during pregnancyNew guidelines for nutrition of management GI symptoms in children with autism The establishment of the Abbott Asia-Pacific Nourishment R&D Center marks a substantial milestone in the Abbott-Singapore partnership.The SPA submission proposes that a composite of cardiovascular mortality and cardiovascular hospitalization serve as the primary endpoint of the trial.
Aldea Pharmaceuticals announces closure of $24M Series B equity financing Aldea Pharmaceuticals, a company pioneering novel therapeutics to take care of aldehyde metabolism disorders, today announced that it has closed a $24 million Series B equity financing. The financing included new traders RusnanoMedInvest and WuXi PharmaTech Corporate Ventures. All previous traders including Canaan Partners and Correlation Ventures participated in the round also.